NCT01826747

Brief Summary

The objective is to test the hypothesis that luteal phase support with vaginal progesterone leads to a higher clinical pregnancy rate (primary outcome) and live birth rate (secondary outcome) when compared to no luteal phase support in a program of intrauterine insemination (IUI) after controlled ovarian stimulation with gonadotrophins. Additionally, the length of the luteal phase will be recorded (secondary outcome) in order to detect luteal phase defects/insufficiencies in the absence of luteal phase suppletion as well as luteal phase prolongation in case of luteal phase support which may be a burden for the patients waiting for the outcome of the treatment.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
393

participants targeted

Target at P75+ for phase_4

Timeline
Completed

Started Apr 2011

Longer than P75 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2011

Completed
1.9 years until next milestone

First Submitted

Initial submission to the registry

February 25, 2013

Completed
1 month until next milestone

First Posted

Study publicly available on registry

April 8, 2013

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2015

Completed
1.4 years until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2016

Completed
Last Updated

October 19, 2018

Status Verified

October 1, 2018

Enrollment Period

3.8 years

First QC Date

February 25, 2013

Last Update Submit

October 17, 2018

Conditions

Keywords

intrauterine inseminationluteal phasegonadotrophins

Outcome Measures

Primary Outcomes (1)

  • clinical pregnancy rate per IUI cycle

    by ultrasound at ± 5 to 6 weeks after IUI

Secondary Outcomes (1)

  • live birth rate per IUI cycle

    40 weeks after IUI

Study Arms (2)

experimental

EXPERIMENTAL

Luteal Phase support

Drug: crinone (progesterone 8%, vaginal application)

control

NO INTERVENTION

No luteal Phase support

Interventions

Eligibility Criteria

Age18 Years - 43 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Patients with an indication for IUI:
  • unexplained infertility
  • mild male factor infertility
  • minimal-mild endometriosis
  • Women:
  • first IUI cycle ever
  • normal ovulatory cycles (26-32d)
  • age\<43,BMI≤30
  • presence of at least one patent tube on hysterosalpingography and/or laparoscopy
  • normal uterine cavity (ultrasound, hysterosalpingography, or laparoscopy)
  • Men: Total motile count ≥ 5 Million/ml after capacitation

You may not qualify if:

  • Patients with contra-indication for pregnancy , infertility or progesterone use.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

UZ Leuven

Leuven, 3000, Belgium

Location

Related Publications (1)

  • Peeraer K, D'Hooghe T, Laurent P, Pelckmans S, Delvigne A, Laenen A, Welkenhuysen M, Wyns C, De Neubourg D. Impact of luteal phase support with vaginal progesterone on the clinical pregnancy rate in intrauterine insemination cycles stimulated with gonadotropins: a randomized multicenter study. Fertil Steril. 2016 Nov;106(6):1490-1495. doi: 10.1016/j.fertnstert.2016.07.1096. Epub 2016 Aug 23.

MeSH Terms

Conditions

Infertility

Interventions

CrinoneProgesterone

Condition Hierarchy (Ancestors)

Genital DiseasesUrogenital Diseases

Intervention Hierarchy (Ancestors)

PregnenedionesPregnenesPregnanesSteroidsFused-Ring CompoundsPolycyclic CompoundsCorpus Luteum HormonesGonadal HormonesHormonesHormones, Hormone Substitutes, and Hormone AntagonistsProgesterone CongenersGonadal Steroid Hormones

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 25, 2013

First Posted

April 8, 2013

Study Start

April 1, 2011

Primary Completion

January 1, 2015

Study Completion

June 1, 2016

Last Updated

October 19, 2018

Record last verified: 2018-10

Locations